EWTX 8-K SEC Filing Analysis

Latest settled — T+20d

EWTX ▲ +1.77% at T+20d

NEUTRAL call ✓ call won +1.77% · α vs SPY -1.37% · entry $35.58 → $36.21

Next anchor: T+60d in 8w

Currently $34.06 · -4.27% from $35.58 entry

Entry anchored
May 7, 08:00 AM ET
via Databento tick

T+1d

-0.73%

call -0.73% · α -1.56%

$35.32

settled 5w ago

T+5d

-5.12%

call -5.12% · α -6.62%

$33.76

settled 27d ago

T+20d

+1.77%

call +1.77% · α -1.37%

$36.21

settled 5d ago

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Edgewise Therapeutics reported Q1 2026 net loss per share of $0.46, beating consensus of -$0.48 by ~4.2%. The pre-revenue biotech highlighted positive long-term sevasemten stabilization data and reiterated key catalysts (CIRRUS-HCM 12-week data in Q2 2026, GRAND CANYON pivotal results in Q4 2026). Cash decreased to $499.6M, with R&D spending up YoY as pipeline programs advanced.

Actionable Insight

No revenue or guidance provided; the stock will trade on upcoming catalysts (CIRRUS-HCM data, GRAND CANYON results). Monitor for Phase 2 HCM data in Q2 2026 and cash runway - current $499.6M should fund operations into late 2026.

Key Facts

Net loss per share $0.46 vs consensus $0.48 beat (5.2% surprise)
Cash, cash equivalents and marketable securities $499.6M as of March 31, 2026
R&D expenses $42.7M (up from $36.8M in Q1 2025) due to increased EDG-7500 and EDG-15400 activity
Net loss widened to $49.0M from $40.8M in Q1 2025
Positive long-term sevasemten data showing functional stabilization up to 3.5 years in Becker MD
CIRRUS-HCM Phase 2 12-week data expected Q2 2026; GRAND CANYON pivotal results Q4 2026

Financial Impact

No revenue; net loss increased ~20% YoY. Cash burn $30.5M during Q1 2026.

net losscashR&D expenses

Risk Factors

Clinical trial failures could impair stock significantly; GRAND CANYON and CIRRUS-HCM are binary events.
Cash burn rate increasing; may require financing within 12-18 months.
Pre-revenue biotech with no approved products - volatility expected.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

83% bullish (18 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001104659-26-056783
Document: tm2613489d1_8k.htm	0001104659-26-056783
Document: 0001104659-26-056783-index-headers.html	0001104659-26-056783
Document: 0001104659-26-056783-index.html	0001104659-26-056783
Document: 0001104659-26-056783.txt	0001104659-26-056783
8-K Data (Synthetic)	0001104659-26-056783

5 reports for EWTX

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for EWTX — sortable, filterable
	Type				Now
Jun 1, 2026 8d ago	8-K BULLISH ★ 8/10	$40.26 $35.59	▼ −11.60%	▼ −8.85%	$34.06 (−15.40%)
May 7, 2026 4w ago	8-K NEUTRAL ★ 4/10	$35.58 $33.76	▼ −5.12%	▼ −6.62%	$34.06 (−4.27%)
Apr 23, 2026 6w ago	DEFA14A NEUTRAL ★ 2/10	$31.58 $30.96	▼ −1.96%	▼ −2.87%	$34.06 (+7.85%)
Mar 27, 2026 10w ago	144 NEUTRAL ★ 3/10	$30.28 $32.50	▲ +7.33%	▲ +3.03%	$34.06 (+12.48%)
Feb 26, 2026 14w ago	8-K NEUTRAL ★ 4/10	$29.66 $28.39	▼ −4.28%	▼ −3.15%	$34.06 (+14.83%)

US Market Status

Market Closed — Opens Thu (11h 13m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access